Tesamorelin 10mg
EXPRESS Apple Pay afterpay
Tesamorelin at a glance
A 44-amino-acid GHRH analogue
Growth hormone-releasing hormone (GHRH) is a signalling peptide associated with the hypothalamicโpituitary endocrine axis. Tesamorelin is a modified GHRH analogue that interacts with the GHRH receptor and stimulates downstream growth hormone signalling.
Tesamorelin is not growth hormone itself and is not a GLP-1 receptor agonist. Its published research focuses on distinct endocrine and metabolic pathways.
GHRH receptor signalling
Tesamorelin has been studied through its interaction with pituitary GHRH receptors, which participate in the regulation of growth hormone secretion.
Growth hormone & IGF-1
Growth hormone stimulation is associated with downstream changes in IGF-1, a circulating growth factor measured in Tesamorelin clinical investigations.
Metabolic research
Published trials have examined CT-measured visceral adipose tissue, metabolic markers and liver-fat measurements in defined HIV-associated patient populations.
These pathways describe published experimental and clinical research. They do not establish that Halo Bio material produces equivalent effects or is suitable for personal use.
What has Tesamorelin research investigated?
Tesamorelin has been evaluated in clinical studies involving adults with HIV-associated excess abdominal fat. These studies primarily investigated changes in visceral adipose tissue and related metabolic measurements, rather than general weight-loss outcomes.
Falutz et al. ยท New England Journal of Medicine (2007)
A 26-week randomised study involving 412 adults with HIV and abdominal-fat accumulation measured visceral adipose tissue using CT imaging. The study reported a 15.2% decrease in the Tesamorelin group compared with a 5.0% increase in the placebo group. These percentages describe a specific imaging endpoint, not total body-weight change.
Falutz et al. ยท Pooled Phase 3 Analysis (2010)
A pooled analysis of two Phase 3 studies involving 806 participants examined changes in visceral adipose tissue, IGF-1 and metabolic measurements. A treatment effect of approximately 15.4% reduction in visceral adipose tissue was reported at 26 weeks.
Stanley et al. ยท JAMA (2014) and The Lancet HIV (2019)
Smaller investigations examined visceral fat and liver-fat measurements in selected populations living with HIV. These studies used defined clinical protocols and imaging endpoints. Their results cannot be extrapolated directly to other populations or research material.
Research involving manufactured clinical formulations does not establish the identity, purity, sterility or suitability of this separately supplied 10mg laboratory vial.
Tesamorelin vs Sermorelin vs CJC-1295 No DAC
These three research peptides are associated with the GHRH signalling pathway, but their molecular structures differ. Tesamorelin is a 44-amino-acid GHRH analogue, while Sermorelin and Modified GRF(1-29), commonly marketed as CJC-1295 No DAC, are shorter 29-amino-acid peptides.
| Characteristic | Tesamorelin | Sermorelin | CJC No DAC |
|---|---|---|---|
| Research name | TH9507 | GRF(1-29) | Modified GRF(1-29) |
| Chain length | 44 amino acids | 29 amino acids | 29 amino acids |
| Research pathway | GHRH signalling | GHRH signalling | GHRH signalling |
| Same molecule? | No | No | No |
Related research pathways do not establish equivalent molecular properties, clinical effects or safety.
Melbourne stock. Nationwide dispatch.
Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is supplied during fulfilment, with delivery timing dependent on destination and carrier.
Tesamorelin research FAQs
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH). It is also known by the development code TH9507.
Research examines pituitary GHRH receptor signalling, growth hormone and IGF-1 responses, and visceral-fat measurements in defined clinical study populations.
GHRH binds receptors in the pituitary gland, stimulating growth hormone secretion. Downstream signalling includes changes in IGF-1, a growth factor measured in Tesamorelin research.
No. Tesamorelin is associated with the growth hormone-releasing hormone pathway, rather than GLP-1 receptor signalling.
Clinical investigations measured deep abdominal fat surrounding internal organs, commonly called visceral adipose tissue, using medical imaging. This is different from measuring overall body-weight reduction.
No. Both are associated with GHRH signalling, but Tesamorelin is a 44-amino-acid molecule while Sermorelin contains 29 amino acids.
No. EGRIFTA is the brand name of specific FDA-approved prescription Tesamorelin formulations. Halo Bio’s 10mg-labelled laboratory material is a separate product and is not an interchangeable medicine.
The 10mg figure represents the nominal labelled quantity. It is not, by itself, a laboratory-confirmed measurement of content, purity or concentration.
No. Halo Bio supplies Tesamorelin as laboratory research material only, not for human or animal consumption, injection, self-administration or clinical treatment.
Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day after payment confirmation.
Independent scientific publications
- Falutz J et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 2007.
Read publication โ - Falutz J et al. Pooled Phase 3 analysis of Tesamorelin in HIV-associated excess abdominal fat. Journal of Clinical Endocrinology & Metabolism, 2010.
- Stanley TL et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients. JAMA, 2014.
- Stanley TL et al. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV. The Lancet HIV, 2019.
- US Food and Drug Administration. EGRIFTA WR (Tesamorelin) prescribing information. Clinical pharmacology and studies.
View prescribing information โ
Laboratory research use only.
Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. The published research cited here does not establish the identity, purity, sterility, safety or performance of this independently supplied material. Refer to product-specific technical documentation for handling and storage requirements.